NCT07054229View on ClinicalTrials.gov

Efficacy and Prognosis of Microwave Ablation Treatment for Papillary Thyroid Microcarcinoma Assessed by Contrast-Enhanced Ultrasound Combined With Genetic and Molecular Diagnostics: A Prospective Observational Study

RecruitingOBSERVATIONAL
Enrollment

480

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Microwave AblationContrast-enhanced UltrasoundGenetic and Molecular DiagnosticsPapillary Thyroid Microcarcinoma
Interventions
DRUG

Contrast enhanced Ultrasound

Contrast Enhanced Ultrasound (CEUS) refers to the observation under ultrasound after the injection of ultrasound contrast agents, such as SonoVue or Lumason.

GENETIC

88-gene panel for thyroid cancer

"88-gene panel refers to a testing combination that includes 88 genes, which are typically associated with the onset, progression, and prognosis of thyroid cancer."

Trial Locations (1)

510120

RECRUITING

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER